Difference between revisions of "Normative:Variant of SARS-CoV-2"
(Created page with "==Normative== === Variants and synonyms === * * ===Definition=== <small>Source:</small> === Encyclopaedic information === <small>Source:</small> ===Examples=== <bloc...") |
(formatting) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
=== Variants and synonyms === | === Variants and synonyms === | ||
* SARS-CoV-2 variant | |||
* | * | ||
| Line 8: | Line 10: | ||
===Definition=== | ===Definition=== | ||
These SARS-CoV-2 variants are designated as variants of concern (VoC) if they are associated with select characteristics, such as increase in transmissibility or virulence, decrease in effectiveness of vaccines and/or therapeutics, or interference with diagnostic test targets. | |||
<small>Source:</small> | <small>Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf</small> | ||
=== Encyclopaedic information === | === Encyclopaedic information === | ||
Emerging data regarding the prevalence and clinical significance of SARS-CoV-2 variants, and the efficacy of monoclonal antibodies against variants, may inform the choice of specific anti-SARS-CoV-2 monoclonal antibody therapy in the future. | |||
<small>Source:</small> | <small>Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf</small> | ||
===Examples=== | ===Examples=== | ||
<blockquote></blockquote><small>Source:</small> | <blockquote>Member States should also strongly discourage all non-essential travel to and from areas with a high prevalence of '''SARS-CoV-2 variants''' of concern or interest and to and from areas with an unknown prevalence due to insufficient sequencing volume.</blockquote><small>Source: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32021H0961</small> | ||
===Collocations=== | ===Collocations=== | ||
* new SARS-CoV-2 variant | |||
* to track SARS-CoV-2 variant | |||
* to study SARS-CoV-2 variant | |||
* | * | ||
| Line 25: | Line 31: | ||
* | * | ||
===Keyness=== | ===Keyness=== | ||
* variant of SARS-CoV-2: >1000 | |||
* SARS-CoV-2 variant: >1000 | |||
* | * | ||
===Note=== | ===Note=== | ||
"SARS-CoV-2 variant" is used more often than variant of "SARS-CoV-2". | |||
Latest revision as of 20:32, 7 March 2022
Normative
Variants and synonyms
- SARS-CoV-2 variant
Definition
These SARS-CoV-2 variants are designated as variants of concern (VoC) if they are associated with select characteristics, such as increase in transmissibility or virulence, decrease in effectiveness of vaccines and/or therapeutics, or interference with diagnostic test targets. Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
Encyclopaedic information
Emerging data regarding the prevalence and clinical significance of SARS-CoV-2 variants, and the efficacy of monoclonal antibodies against variants, may inform the choice of specific anti-SARS-CoV-2 monoclonal antibody therapy in the future. Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
Examples
Member States should also strongly discourage all non-essential travel to and from areas with a high prevalence of SARS-CoV-2 variants of concern or interest and to and from areas with an unknown prevalence due to insufficient sequencing volume.
Source: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32021H0961
Collocations
- new SARS-CoV-2 variant
- to track SARS-CoV-2 variant
- to study SARS-CoV-2 variant
Keyness
- variant of SARS-CoV-2: >1000
- SARS-CoV-2 variant: >1000
Note
"SARS-CoV-2 variant" is used more often than variant of "SARS-CoV-2".